| 1 |
35614983 | FIP-fve Stimulates Cell Proliferation and Enhances IL-2 Release by Activating MAP2K3/p38α (MAPK14) Signaling Pathway in Jurkat E6-1 Cells. | 2022 |
1 |
| 2 |
29045288 | Effects of Anti-Inflammatory Medications in Patients With Coronary Artery Disease: A Focus on Losmapimod. | 2018 May/Jun |
1 |
| 3 |
29155150 | Enhancement of cutaneous immunity during aging by blocking p38 mitogen-activated protein (MAP) kinase-induced inflammation. | 2018 Sep |
1 |
| 4 |
29566026 | The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial. | 2018 |
2 |
| 5 |
27230767 | Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit? | 2017 Feb |
1 |
| 6 |
29206629 | Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD. | 2017 Sep |
1 |
| 7 |
27043082 | Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. | 2016 Apr 19 |
1 |
| 8 |
25751578 | A randomized, placebo-controlled trial of the analgesic efficacy and safety of the p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain from lumbosacral radiculopathy. | 2015 Apr |
1 |
| 9 |
25965709 | Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. | 2015 May |
2 |
| 10 |
26273189 | Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod. | 2015 |
3 |
| 11 |
24699061 | Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach. | 2014 Jun |
4 |
| 12 |
24930728 | Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. | 2014 Sep 27 |
3 |
| 13 |
25164947 | A low-frequency variant in MAPK14 provides mechanistic evidence of a link with myeloperoxidase: a prognostic cardiovascular risk marker. | 2014 Aug 27 |
1 |
| 14 |
23239139 | Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study. | 2013 Jul |
2 |
| 15 |
23254770 | Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases. | 2013 Mar |
1 |
| 16 |
22090363 | An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. | 2012 Mar |
1 |
| 17 |
22974804 | Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. | 2012 Sep |
1 |
| 18 |
21262998 | Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. | 2011 Feb 8 |
2 |